Table 2 Variation of cholesterol distribution in plasma lipoproteins after ciprofibrate treatment.

CIII

control

30.6 ± 6.0 (24.6)

16.8 ± 1.0 (13.6)

76.6 ± 6.0 (61.8)

0.6

treated

47.1 ± 2.4 (46.2)^a

20.4 ± 6.0 (20.0)

34.4 ± 9.5 (33.7)^a

2.0

CIII/CETP

control

20.8 ± 5.0 (20,8)

26.2 ± 8.0 (26.2)

52.9 ± 10.1 (52.9)

0.9

treated

53.3 ± 8.4 (57.9)^a

9.3 ± 2.0 (10.1)^b

29.3 ± 8.0 (32.0)^a

2.1

CETP

control

1.7 ± 0.2 (2.2)

12.8 ± 2.1 (16.2)

64.5 ± 4.3 (81.6)

0.2

treated

1,8 ± 0,1(2.3)

8.9 ± 0.4 (11.5)^a

67.3 ± 4.8 (86.2)

0.2

non-Tg

control

3.6 ± 0.8 (4.9)

6.5 ± 2.8 (8.8)

63.8 ± 6.2 (86.3)

0.2

treated

3.3 ± 0.4 (3.6)

16.7 ± 2.2 (18.0)^a

72.9 ± 5.0 (78.4)^a

0.3